Risk factors for cardiovascular disease in patients with non-alcoholic fatty liver disease with polymorbidity

Aim. To study the associations of the frequency and values of parameters of the main risk factors (RF) of cardiovascular diseases (CVD) and the degree of transnosological polymorbidity (PM) in patients with nonalcoholic fatty liver disease (NAFLD).

Material and methods. The analysis of 3667 medical records (men, women) treated in the clinic of Research Institute of Experimental and Clinical Medicine (Novosibirsk) was carried out. Index of polymorbidity was evaluated by the number of nosological forms in accordance with the International Classification of Diseases, 10th revision (ICD-10). The following risk factors were assessed according to clinical and laboratory tests: arterial hypertension, dyslipidemia, hyperglycemia, obesity.

Results. Both among men and women with increasing index of PM there was identified growth of the parameters that determine the main RF: systolic BP, diastolic BP, obesity (both in men and women), atherogenicity index (in women), glucose concentration in the blood serum (in women). Frequency of AH occurrence in persons with a high degree of PM among men was 49%, and among women — 69% higher, compared with persons with a low degree of PM. Among men, there was an increase in the incidence of AH (by 9%) and obesity (by 9%) in individuals with a high degree of PM, compared with individuals with an average degree of PM. Among women, there was an increase in the incidence of AH (by 15%), obesity (by 9%), hyperglycemia (by 11%) in persons with a high degree of PM, compared with individuals with an average degree of PM.

Conclusion. There was established the role of risk factors for cardiovascular diseases, arterial hypertension mainly, in the development of polymorbidity in patients with NAFLD. The findings indicate the need for personified prevention and treatment of such patients with mandatory identification and correction of modifiable CVD RF.

1. Belyalov FI. Treatment of internal diseases in terms of comorbidity. Moscow: GEOTAR-Media, 2016. p. 544 (In Russ.). ISBN 9785-9704-4010-0.

2. Barnett K, Mercer SW, Norbury M, et al. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet. 2012;380(9836):37-43. doi: 10.1016/S0140-6736(12)60240-2.

3. Fortin M, Stewart M, Poitras M-E, et al. Systematic review of prevalence studies on multimorbidity: toward a more uniform methodology. Ann Fam Med. 2012;10(2):142-51. doi:10.1370/afm.1337.

4. Oganov RG, Maslennikova GYa. Polymorbidity: specifics of co-development and concomitance of several diseases in one patient. Cardiovascular Therapy and Prevention. 2016; 15(4):4-9. (In Russ.) doi:10.15829/1728-8800-2016-4-4-9.

5. Sevost'yanova EV, Nikolaev YuA, Mitrofanov IM, et al. The role of risk factors for chronic non-infectious diseases in the development of transnosological polymorbid pathology in a modern therapeutic clinic. Clinical medicine. 2017;8:735-41. (In Russ.)

6. Nadasdi A, Somogyi A, Igaz P, et al. Non-alcoholic fatty liver disease — a summary and update based on the EASL-EASD-EASO Clinical Practice Guidelines of 2016. Orv Hetil. 2018;159(45):1815-30. doi:10.1556/650.2018.31231.

7. Sao R, Aronow WS. Association of non-alcoholic fatty liver disease with cardiovascular disease and subclinical atherosclerosis. Arch. Med.Sci. 2018;14(6):1233-44. doi:10.5114/aoms.2017.68821.

8. Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol. 2008;49:608-12. doi: 10.1016/j.jhep.2008.06.018. Epub 2008 Jul 9.

9. Gaggini M, Morelli M, Buzzigoli E, et al. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients. 2013;5:1544-60.

10. Bhatia LS, Curzen NP, Calder PC, et al. Non-alcoholic fatty liver disease: a new and 13. important cardiovascular risk factor? Eur Heart J. 2012;33:1190-200. doi:10.1093/eurheartj/ehr453. Epub 2012 Mar 8.

11. Ivashkin VT, Maevskaya MV, Pavlov ChS, et al. Clinical recommendations for the diagnosis and treatment of non-alcoholic fatty liver disease of the Russian Society for the Study of the Liver and the Russian Gastroenterological Association. 14. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016;26(2):24-42. (In Russ.)

12. Mikheeva OM, Komissarenko IA. Metabolic syndrome as a problem of polymorbidity. Effective pharmacotherapy. Cardiology and angiology. 2013;3(43):12-8. (In Russ.)

13. Efremov LI, Komisarenko IA. Metabolic continuum and polymorbidity in geriatrics. Experimental and clinical gastroenterology. 2014; 106(6):4-7. (In Russ.)

14. Zhang HN, Xu QQ, Thakur A, et al. Endothelial dysfunction in diabetes and hypertension: Role of microRNAs and long non-coding RNAs. Life Sci. 2018;213:258-68. doi:10.1016/j.lfs.2018.10.028.

15. Makadia SS, Blaha M, Keenan T, et al. Relation of hepatic steatosis to atherogenic dyslipidemia. Am J Cardiol. 2013;12(10):1599-604. doi:10.1016/j.amjcard.2013.08.001.